Studies found that targeting CXCL12/CXCR4 signaling by an OV expressing CXCR4 antagonist effectively disrupted the tumor vasculature, induced ICD of cancer cells, reversed immunosuppressive TME and improved antitumor immunity, including inhibition of cancer metastasis [86, 87]. The gene discussed is CXCL12; the disease is neoplasm.